Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study)
ConclusionsLong-term treatment with low-dose aspirin did not reduce the composite primary endpoint; however, there were reductions in secondary endpoints with fewer coronary events and renal outcomes.ClinicalTrials.gov Identifier: NCT01709994.
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
More News: Aspirin | Bleeding | Cardiology | Cardiovascular | Chronic Kidney Disease | Clinical Trials | Diabetes | Diabetes Mellitus | Endocrinology | Heart | Heart Failure | Study | Urology & Nephrology